RxDoctor Payments Data

Christine Cox, DO

Endocrinology, Diabetes & Metabolism · Aurora, ILNPI 1154620458

Payments from drug & device makers

$178in general payments, 2019–2025

Across 4 payments — averaging $44.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$101
  • Medtronic$77
$75in research payments, 2019–2025

Across 2 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$38
  • Novo Nordisk$38

What the payments were for

  • Food & beverage$178100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$101
Medtronic3$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178 in reported general payments places this provider in the 25th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois

Medicare billing

Part B allowed, 2024
$332,573
Medicare patients
424
Services billed
19,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin345$447,522
OzempicSemaglutide263$407,511
MounjaroTirzepatide260$346,947
Tresiba Flextouch U-100Insulin Degludec72$57,900
Lantus SolostarInsulin Glargine,hum.Rec.Anlog306$53,436
JanuviaSitagliptin Phosphate42$51,456
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$49,773
TrulicityDulaglutide30$43,810
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/741$42,453
Fiasp FlextouchInsulin Aspart (Niacinamide)32$40,764
Novolog FlexpenInsulin Aspart92$33,435
Humalog Kwikpen U-100Insulin Lispro96$29,677
FarxigaDapagliflozin Propanediol19$25,115
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$19,552
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$18,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$101$420,435289 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →